On Wednesday, Hims & Hers Health (HIMS.US) rose more than 5% to a record high of $32.23.
The Zhitong Finance App learned that on Wednesday, Hims & Hers Health (HIMS.US) rose more than 5%, continuing to reach a record high of $32.23. According to the news, Hunterbrook Media, an agency that “targets short seller Citron,” released a report on Monday stating that Trump nominated Marty Makary as the director of the US Food and Drug Administration (FDA), and Hims & Hers may benefit greatly from this nomination because Makary is an executive of Sesame Inc., and Sesame is a startup that sells compound GLP-1 diet pills.
Hunterbrook Capital, a hedge fund owned by Hunterbrook, said they are now optimistic about Hims & Hers stock, contrary to their June shorting position. At the time, they were concerned about GLP-1 injections sold by the company online.
